Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results
Authors:
Open Access
- 28 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (9) , 1231-1242
Abstract
Neurally meditated reflex or neurocardiogenic or vasovagal syncope (NMS) is usually mediated by a massive vagal reflex. This study reports the long-term outcome of NMS therapy based on endocardial radiofrequency (RF) catheter ablation of the cardiac vagal nervous system aiming permanent attenuation or elimination of the cardioinhibitory reflex (cardioneuroablation). A total of 43 patients (18F/25M, 32.9 ± 15 years) without apparent cardiopathy (left ventricular ejection fraction=68.6 ± 5%) were included. All had recurrent NMS (4.7 ± 2 syncope/patient) with important cardioinhibition (pauses=13.5 ± 13 s) at head-up tilt test (HUT), normal electrocardiogram (ECG), and normal atropine test (AT). The patients underwent atrial endocardial RF ablation using spectral mapping to track the neurocardiac interface (AF Nest Mapping). The follow-up (FU) consisted of clinical evaluation, ECG (1 month/every 6 months/or symptoms), Holter (every 6 months/or symptoms), HUT (≥4 months/or symptoms), and AT (end of ablation and ≥6 months). A total of 44 ablations (48 ± 9 points/patient) were performed. Merely three cases of spontaneous syncope occurred in 45.1 ± 22 months (two vasodepressor, one undefined). Only four partial cardioinhibitory responses occurred in post-ablation HUT without pauses or asystole (sinus bradycardia). Long-term AT (21.7 ± 11 months post) was negative in 33 (76.7%, P < 0.01), partially positive in 7(16.3%), and normal in three patients only (6.9%) reflecting long-term vagal denervation (AT-Δ%HR pre 79.4% × 23.2% post). The post-ablation stress test and Holter showed no abnormalities. No major complications occurred. Endocardial RF catheter ablation of severe neurally meditated reflex syncope prevented pacemaker implantation and showed excellent long-term results in well selected patients. Despite no action in vasodepression it seems to cause enough long-term vagal reflex attenuation, eliminating the cardioinhibition, and keeping most patients asymptomatic. Indication was based on clinical symptoms, reproduction of severe cardioinhibitory syncope, and normal atropine response.Keywords
This publication has 40 references indexed in Scilit:
- Prevention of Syncope Trial (POST)Circulation, 2006
- Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled studyEP Europace, 2006
- Neurocardiogenic syncopeBMJ, 2004
- Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal SyncopeJAMA, 2003
- Incidence and Prognosis of SyncopeNew England Journal of Medicine, 2002
- Mechanism of Syncope in Patients With Isolated Syncope and in Patients With Tilt-Positive SyncopeCirculation, 2001
- Diagnostic value of history in patients with syncope with or without heart diseaseJACC, 2001
- Observations on recurrent syncope and presyncope in 641 patientsThe Lancet, 2001
- Vagal and Sympathetic Mechanisms in Patients With Orthostatic Vasovagal SyncopeCirculation, 1997
- Neural Monitoring of Vasovagal SyncopePacing and Clinical Electrophysiology, 1997